Targeted Liposomal Delivery of Docetaxel with Enhanced Cellular Uptake and Retention

A next-generation liposomal composition for targeted delivery of docetaxel to tumour sites, featuring a novel membrane-permeable peptide for enhanced cellular uptake and retention, improved drug loading and stability, and selective binding to cancer cells.

The original patent disclosed a liposomal composition with high drug loading, but it had limitations in terms of cellular uptake and retention. The new inventive concept addresses these limitations by introducing a novel membrane-permeable peptide that enhances cellular uptake and retention, thereby improving the efficacy of docetaxel delivery.

The new inventive concept comprises a liposomal composition with a novel membrane-permeable peptide that facilitates cellular uptake and retention of docetaxel. The peptide is conjugated to the liposome surface, allowing for targeted delivery to tumour sites. The liposomal composition also features a combination of ionic and non-ionic surfactants, a pH-sensitive liposome formulation, and a targeting moiety that selectively binds to cancer cells. The novel amino acid-based buffer in the reconstitution buffer ensures optimal pH conditions for drug release.

The new claims introduce a novel membrane-permeable peptide, a pH-sensitive liposome formulation, and a targeting moiety that selectively binds to cancer cells, which are not obvious from the original patent. These features provide a significant improvement in cellular uptake and retention, making the new inventive concept a paradigm shift in targeted liposomal delivery of docetaxel.

Alternative embodiments of the inventive concept could include using different types of targeting moieties, such as aptamers or small molecules, or modifying the liposome surface with other functional groups to enhance cellular uptake and retention. Variations of the pH-sensitive liposome formulation could also be explored to optimize drug release kinetics.

The new inventive concept has significant commercial potential in the oncology market, particularly in the treatment of solid tumours. The targeted delivery of docetaxel could lead to improved efficacy and reduced toxicity, making it an attractive option for cancer patients. The pharmaceutical industry could benefit from this technology, and potential partnerships with biotech companies could accelerate its development and commercialization.